Drug EfficacyNVL-655 demonstrates robust efficacy with an overall response rate of 54% in patients with ALK resistance mutations, and strong central nervous system activity with a response rate of 52% in patients with CNS metastases.
Market PotentialAnalyst upgrades NVL to Outperform with expectations of NVL-655 becoming a multiblockbuster lung cancer agent, potentially achieving peak sales of around $6.1bn in ALK+ NSCLC across lines.
Safety And TolerabilityThe safety profile of NVL-655 is relatively clean, showing promise with low percentages of serious liver enzyme increases, avoidance of TRK-related adverse events, and very few dose discontinuations and reductions.